Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions
- 1 May 2000
- journal article
- case report
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 42 (5) , 829-830
- https://doi.org/10.1067/mjd.2000.105948
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- An important role of tumor necrosis factor-α in the induction of adhesion molecules in psoriasisArchives of Dermatological Research, 1998
- Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basisNature Medicine, 1995
- Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesionsClinical and Experimental Immunology, 1994
- Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium.The Journal of Experimental Medicine, 1993